EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Prediction of pathological complete response to chemotherapy for breast cancer using deep neural network with uncertainty quantification

Bowen Jing, Kai Wang, Erich Schmitz, Shanshan Tang, Yunxiang Li, You Zhang, Jing Wang

Medical Physics · 2024

DOI: 10.1002/mp.17451 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Physics, 2024. Verfasst von Bowen Jing und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Deep Learning. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The I‐SPY 2 trial is a national‐wide, multi‐institutional clinical trial designed to evaluate multiple new therapeutic drugs for high‐risk breast cancer. Previous studies suggest that pathological complete response (pCR) is a viable indicator of long‐term outcomes of neoadjuvant chemotherapy for high‐risk breast cancer. While pCR can be assessed during surgery after the chemotherapy, early prediction of pCR before the completion of the chemotherapy may facilitate personalized treatment management to achieve an improved outcome. Notably, the acquisition of dynamic contrast‐enhanced magnetic resonance (DCEMR) images at multiple time points during the I‐SPY 2 trial opens up the possibility of achieving early pCR prediction.

Purpose

In this study, we investigated the feasibility of the early prediction of pCR to neoadjuvant chemotherapy using multi‐time point DCEMR images and clinical data acquired in the I‐SPY2 trial. The prediction uncertainty was also quantified to allow physicians to make patient‐specific decisions on treatment plans based on the level of associated uncertainty.

Methods

The dataset used in our study included 624 patients with DCEMR images acquired at 3 time points before the completion of the chemotherapy: pretreatment (T0), after 3 cycles of treatment (T1), and after 12 cycles of treatment (T2). A convolutional long short‐term memory (LSTM) network‐based deep learning model, which integrated multi‐time point deep image representations with clinical data, including tumor subtypes, was developed to predict pCR. The performance of the model was evaluated via the method of nested 5‐fold cross validation. Moreover, we also quantified prediction uncertainty for each patient through test‐time augmentation. To investigate the relationship between predictive performance and uncertainty, the area under the receiver operating characteristic curve (AUROC) was assessed on subgroups of patients stratified by the uncertainty score.

Results

By integrating clinical data and DCEMR images obtained at three‐time points before treatment completion, the AUROC reached 0.833 with a sensitivity of 0.723 and specificity of 0.800. This performance was significantly superior ( p < 0.01) to models using only images (AUROC = 0.706) or only clinical data (AUROC = 0.746). After stratifying the patients into eight subgroups based on the uncertainty score, we found that group #1, with the lowest uncertainty, had a superior AUROC of 0.873. The AUROC decreased to 0.637 for group #8, which had the highest uncertainty.

Conclusions

The results indicate that our convolutional LSTM network‐based deep learning model can be used to predict pCR earlier before the completion of chemotherapy. By combining clinical data and multi‐time point deep image representations, our model outperforms models built solely on clinical or image data. Estimating prediction uncertainty may enable physicians to prioritize or disregard predictions based on their associated uncertainties. This approach could potentially enhance the personalization of breast cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsDeep LearningHumansUncertaintyMagnetic Resonance ImagingNeural Networks, ComputerTreatment OutcomeFemaleAntineoplastic AgentsNeoadjuvant Therapy

Stichwörter der Autor:innen

ResNetbreastpathological complete responsepredictionuncertainty quantification

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Advanced Imaging and Informatics for Radiation Therapy (AIRT) Lab, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Förderung

  • NCI NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Jing, B., Wang, K., Schmitz, E., Tang, S., Li, Y., Zhang, Y., & Wang, J. (2024). Prediction of pathological complete response to chemotherapy for breast cancer using deep neural network with uncertainty quantification. Medical Physics. https://doi.org/10.1002/mp.17451

Vancouver

Jing B, Wang K, Schmitz E, Tang S, Li Y, Zhang Y, et al. Prediction of pathological complete response to chemotherapy for breast cancer using deep neural network with uncertainty quantification. Medical Physics. 2024. doi:10.1002/mp.17451

BibTeX
@article{Jing2024,
  author = {Jing, Bowen and Wang, Kai and Schmitz, Erich and Tang, Shanshan and Li, Yunxiang and Zhang, You and Wang, Jing},
  title = {Prediction of pathological complete response to chemotherapy for breast cancer using deep neural network with uncertainty quantification},
  journal = {Medical Physics},
  year = {2024},
  doi = {10.1002/mp.17451}
}
Kostenlos starten →